Twist Bioscience Q3 Revenue Jumps 23% to $118M, But Losses Widen; CEO Adopts 10b5-1 Plan
TWST has more than doubled off its 52-week low of $23.3.
Summary
Twist Bioscience reported Q3 FY2026 revenue of $118.4M (+23% YoY) but swung to a net loss of $35.1M. The CEO, President, and a director adopted 10b5-1 plans for potential sales of up to 720,906 shares, adding to recent insider selling.
Key Events · Earnings and Guidance · TWST
-
Revenue Growth, But Losses Widen
Q3 revenue rose 23% to $118.4M, but the company posted a net loss of $35.1M vs. a $20.4M profit a year ago. Nine-month net loss widened to $109.6M from $50.5M.
-
Gross Margin Pressure
Gross margin declined to 52.8% from 53.4% in Q3 FY2025, primarily due to customer mix, despite higher revenues.
-
Cash Burn Accelerates
Cash, equivalents, and short-term investments fell to $166.8M from $232.4M at fiscal year-end. Operating cash burn was $41.3M for nine months, up from $35.8M.
-
CEO and Insiders Adopt 10b5-1 Plans
CEO Emily Leproust adopted a plan to sell up to 624,134 shares; President Patrick Finn up to 78,355 shares; Director Robert Chess up to 18,417 shares. This follows $12.6M in insider sales over the past 90 days.
Analysis · TWST · Life Sciences
Record quarterly revenue of $118.4 million—a 23% year-over-year surge—underscores robust demand in DNA synthesis and NGS applications. Yet the top-line strength was overshadowed by a swing to a net loss of $35.1 million, compared with a profit a year ago, pushing the nine-month loss to $109.6 million. Gross margin slipped to 52.8% from 53.4%, pressured by customer mix. Cash reserves contracted to $166.8 million from $232.4 million at fiscal year-end, though management asserts sufficient liquidity for at least 12 months. In a separate development, the CEO, President, and a director adopted 10b5-1 trading plans covering up to 720,906 shares combined, extending a pattern of insider selling that has exceeded $12.6 million in the past 90 days. While the $200 million ATM program remains untapped, the shelf registration and insider selling plans create an overhang.
At the time of this filing, TWST was trading at $101.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $23.30 to $105.47. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.